The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Differences in presentation and management patterns in patients with hepatocellular carcinoma (HCC): Data from HCC registry in Asia.
 
Pierce K. H. Chow
Honoraria - Guerbet; QuintilesIMS; Sirtex Medical
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; MSD; Oncosil; Roche; Sirtex Medical
Speakers' Bureau - Sirtex Medical
Research Funding - IQVIA (Inst); New B Innovation (Inst); Sirtex Medical (Inst)
 
Lequn Li
Research Funding - Idenix (Inst)
 
Jiangtao Li
Research Funding - Idenix (Inst)
 
Fan Jia
Research Funding - Idenix (Inst)
 
Hee-Jee Wang
Research Funding - Idenix (Inst)
 
Kiyoshi Hasegawa
Research Funding - Idenix (Inst)
 
Jin-Mo Yang
Research Funding - Idenix (Inst)
 
Poh-Seng Tan
Research Funding - Idenix (Inst)
 
Shukui Qin
No Relationships to Disclose
 
Kwang-Hyub Han
Research Funding - Idenix (Inst)
 
Brian Goh
Research Funding - Idenix (Inst)
 
Ho Seong Han
Research Funding - Idenix (Inst)
 
Junji Furuse
Honoraria - Astellas Pharma; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; EA Pharma; Eisai; Lilly Japan; Merck Serono; Mochida Pharmaceutical Co. Ltd.; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Sawai Pharmaceutical Co; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Eisai; Fujifilm; J-Pharma; Kyowa Hakko Kirin; MSD; Novartis; Ono Pharmaceutical; Otsuka; Sandoz; Sanofi; Sawai Pharmaceutical Co; Shionogi; Shire; Sumitomo Dainippon; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Astellas Pharma (Inst); Baxalta/Shire (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); J-Pharma (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); MSD (Inst); NanoCarrier (Inst); Novartis (Inst); OncoTherapy Science (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst); Zeria Pharmaceutical (Inst)
 
Xu Zhu
Research Funding - Idenix (Inst)
 
Joanna Zhi Jie Ling
Research Funding - Idenix (Inst)
 
Mihir Gandhi
Research Funding - Idenix (Inst)